Tell Mobile análises de aplicativos para 30 de outubro

TELL is a validated digital speech biomarker platform for researchers and clinicians studying brain health, cognition, and neurodegenerative disease. In just a few minutes of recorded speech, TELL captures 130+ acoustic and linguistic markers linked to conditions such as Alzheimer's disease, Parkinson's disease, aphasia, and other cognitive and mood disorders. The app guides participants through a structured protocol of speech tasks and a linguistic profile survey, then returns real-time visualizations for clinical use and downloadable datasets for research. KEY FEATURES: Structured speech protocol — An 11-task battery (including picture description, verbal fluency, and narrative speech) validated in peer-reviewed research and deployed across high-income and low/middle-income countries. Flexible administration — Run sessions in-clinic with an examiner, or let participants complete them remotely and unsupervised, using the same protocol. Multilingual — Available in English, Spanish, Portuguese, and French, with additional languages added for specific projects. Real-time and offline outputs — Clinicians get plotted metrics as soon as a session ends; researchers can export raw audio, transcripts, and derived features for offline analysis. Built for data protection — TELL follows core PHI/HIPAA-aligned data handling practices, with account-based access and controls on who can view protected data. Backed by science — TELL's tasks and metrics have been described in peer-reviewed methodology papers and validated across multiple countries and languages, with 80+ related publications and deployments spanning universities, hospitals, pharmaceutical studies, and public health programs. WHO IT'S FOR TELL is built for research teams, clinicians, and health systems evaluating speech and language as a window into brain health — not for casual or unsupervised consumer use. Results are intended to support, not replace, the judgment of a qualified professional, and TELL does not provide a diagnosis. GETTING STARTED Access to TELL is provided through a licensed account. Visit tellapp.org to request access for your project — free research licenses are available for scientific studies, alongside commercial licenses for clinical and institutional use. TELL is developed by TELL Toolkit Inc., in collaboration with research partners worldwide.